GLP-1 Guides & Education
Evidence-based, plain-language guides covering how GLP-1 medications work, their side effects, and how to get the best results. Written for patients, not pharma reps.
How GLP-1 Medications Work
The science behind semaglutide and tirzepatide explained in plain language. How these drugs reduce appetite, slow gastric emptying, and change your relationship with food.
Food Noise Explained
The constant mental chatter about food that GLP-1 drugs quiet. What food noise is, why it matters, and how patients describe the experience of it disappearing.
Ozempic Face: What It Is and How to Prevent It
Rapid facial volume loss is a real side effect of fast weight loss on GLP-1 drugs. Learn why it happens, who is most at risk, and what dermatologists recommend.
Muscle Loss Prevention on GLP-1
Up to 40% of weight lost on GLP-1 drugs can be lean mass. Evidence-based strategies for preserving muscle through protein intake, resistance training, and dosing.
GLP-1 and Alcohol: What You Need to Know
Many patients report dramatically reduced desire to drink. Explore the emerging research on GLP-1 drugs and alcohol consumption, plus safety considerations.
GLP-1 and Exercise: Maximizing Your Results
How to combine GLP-1 medications with the right exercise routine. Evidence-based protocols for resistance training, cardio, and recovery while on treatment.
GLP-1 Medications and PCOS
Emerging evidence on GLP-1 drugs for polycystic ovary syndrome. How these medications may improve insulin resistance, hormonal balance, and fertility outcomes.
GLP-1 Before Surgery: What to Know
Why anesthesiologists are concerned about GLP-1 drugs before surgery. Guidelines on when to stop, aspiration risks, and how to talk to your surgical team.
GLP-1 Heart Benefits
Beyond weight loss: how GLP-1 medications reduce cardiovascular risk. The SELECT trial data, FDA label updates, and what it means for heart health.
Weight Regain After Stopping GLP-1
What the clinical data says about weight regain after discontinuation, how to taper safely, and lifestyle strategies to maintain your results long-term.
Orforglipron: The Next Oral Weight Loss Pill
Eli Lilly's oral non-peptide GLP-1 drug needs no empty stomach or fasting window. Phase 3 results, FDA timeline (PDUFA April 2026), pricing estimates, and how it compares.
Retatrutide: The Triple-Action Weight Loss Drug
The first triple GLP-1/GIP/glucagon agonist showing up to 28.7% body weight loss in Phase 3. Timeline, safety data, and comparison to tirzepatide and semaglutide.
Looking for Provider Reviews?
We independently review every major GLP-1 telehealth program on safety, cost, transparency, and medical support.